Furthermore, the developed BDMSN-MLFIA showed no cross-reactivity with common tumor markers (AFP, CA 199, CEA), and the clinical test results demonstrated a correlation coefficient of over 98% when compared with commercial electrochemiluminescence methods. The gene discussed is CEACAM5; the disease is neoplasm.